Bone sarcoma characteristics and distribution in beagles injected with radium-226.

A total of 155 primary bone sarcomas were found in 131 of the 246 beagles injected with 226Ra and 5 primary bone sarcomas were found in 4 of the 158 unexposed controls. Of these 155 bone sarcomas, 146 (94%) were osteosarcomas and 9 were non-osteosarcomas. An additional 31 primary bone sarcomas (28 osteosarcomas) developed in 44 dogs terminated from the main study because of limb amputation for bone sarcoma. Non-osteosarcomas predominated in both the controls and the second lowest of six logarithmically increasing dose levels (there were no bone sarcomas in the lowest dose group). Osteosarcomas predominated at the higher dose levels, and incidence tended to increase as dose increased. The 146 osteosarcomas were distributed quite evenly between males and females (72:74). Of the 9 non-osteosarcomas, 6 occurred in males and 3 in females. The ratio of bone sarcomas of the appendicular skeleton to those in the axial skeleton was 110:45, with osteosarcomas occurring more often in the appendicular skeleton (108:38). Cases of multiple primary bone sarcomas in dogs injected with 226Ra were found only in the four highest dose groups. Amputations were performed on 44 of the 96 dogs (94 injected and 2 unexposed) that developed appendicular bone sarcomas. A statistical study of the distribution of bone sarcomas among 16 separate bone groups showed a statistically significant correlation to cancellous skeletal surface, but the variability among bone groups was too large for this relationship to be of real predictive value. It is postulated that the distribution of bone sarcomas reflects primarily the relative cell division rates in the bone groups and secondarily the radiation dose distribution, with the highest occurrence of bone sarcoma in the humeri, pelvis, femora and tibiae/fibular tarsal, and no occurrence in the coccygeal vertebrae, sternum, forepaws or hindpaws.

Bone sarcoma characteristics and distribution in beagles fed strontium-90.

A total of 66 primary bone sarcomas were diagnosed in 47 beagles; 43 of these dogs were part of the 403 beagles fed 90Sr and 4 were part of the 162 controls. Multiple primary bone sarcomas were found in 15 of the 47 beagles (32%). The incidence of multiple primary bone sarcoma was restricted to the two highest dose groups, except for a single control dog which developed two bone sarcomas. A threshold-like radiation dose response was observed; no sarcomas were observed in the lowest three dose groups, but the number of primary bone sarcomas increased rapidly in the higher dose groups. Of the 66 primary sarcomas, 49 were osteosarcomas (74%). As the dose increased, the proportion of osteosarcomas increased sharply, 4/10 (40%), 26/29 (90%), and 16/18 (89%), in the three highest dose groups. Thirteen of the bone sarcomas of other types occurred in males, and 4 in females, whereas 21 osteosarcomas occurred in males, and 28 in females. The ratio of bone sarcomas of the appendicular skeleton to those in the axial skeleton was 40:26, with osteosarcomas occurring more often in the appendicular than the axial skeleton (32:17), whereas nonosteogenic tumors showed no predilection (8:9). A statistical study of the distribution of bone sarcomas among 16 separate bone groups showed a correlation only with the distribution of cancellous bone volume-to-surface ratio and not with either skeletal mass distribution or dose distribution. The highest occurrence of sarcomas was in the humeri, femora, and mandible, and no occurrence in the coccygeal vertebrae, paws, or sternum. It is postulated that the distribution of bone sarcomas reflects a critical combination of the osteosarcoma precursor cell population, their cell division rate, and the radiation dose absorbed by these cells.

Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).

beta-emitting 166Ho (t1/2 = 26.78 hours, E(beta)max = 1.8 MeV) complexed with the phosphonic acid chelator, 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) (DOTMP) at a ligand-to-metal ratio of 1.5:1 binds to bone. This radioactive complex is a marrow-ablating radiopharmaceutical that appears useful for preparation of bone marrow (BM) transplant recipients without the morbidity usually associated with total body irradiation preparatory regimens. We have found with seven splenectomized young adult beagle dogs that a 166Ho radiopharmaceutical dosage of 370 MBq/kg body weight provides an initial skeletal radioactivity burden of at least 1.5 GBq/kg skeleton and results in complete ablation of hematopoietic marrow cell populations within 7 days. The beta particle flux distribution in BM-forming skeletal tissue is not uniform. Red marrow radiation doses varied from 30 to 115 Gy as estimated by direct radioassay and autoradiographic analyses of both bone biopsies and postmortem samples; the median value of 61 Gy agreed with our theoretical expectations. In vivo radioactivity distribution was evaluated with nuclear imaging methods. Apparently, normal hematopoiesis was restored in three dogs with autologous BM transplants performed 5 to 6 days after administration of the marrow ablative radiopharmaceutical, 166Ho-DOTMP. BM biopsies at 7 to 10 months posttransplantation indicate continued normal hematopoietic activity.

Skeletal uptake and lifetime retention of 90Sr and 226Ra in beagles.

Skeletal uptake and retention of graded doses of ingested or injected 90Sr and injected 226Ra have been studied in 863 beagles; measurements of skeletal burden were made up to a maximum lifetime of 18.5 years. Doses ranged from 0 in 162 controls to levels that markedly reduced life span. Skeletal uptake of the administered doses averaged 2 to 2.3% for 90Sr fed to 388 beagles from midgestation to age 540 days, 33 to 35% for 45 dogs that were given single intravenous injections of 90Sr at age 540 days, and 37 to 45% for 226Ra given in eight fortnightly intravenous injections to 253 dogs from age 435 to 540 days. Skeletal retention was evaluated from the time when uptake ended until death, which occurred, on the average, at 14 to 14.5 years for the lower levels. Simple two-parameter power functions of the form SB(t) = at-b, with SB the skeletal burden, t the time after beginning of intake, and a and b fitted parameters, but corrected for radioactive decay, were used to describe the whole-skeleton retention of deposited 90Sr or 226Ra, as well as in 17 skeletal subgroups. The negative logarithmic slope, b, of these power functions for whole skeleton was about the same for both 90Sr and 226Ra, with an average value of 0.30 +/- 0.05 SD, indicating a common clearance mechanism. The lifetime average cumulative absorbed dose to irradiated skeleton varied from 0.38 to 107 Gy for beta rays in the 90Sr studies and from 0.94 to 167 Gy for alpha particles in the 226Ra studies. Daily dose rates to the skeleton for singly injected 90Sr fell rapidly after injection and declined to about 10% of the peak values late in life. Rates declined more slowly to 40-50% of peak values in other treatment groups. The time-weighted average dose rate for fed 90Sr and injected 226Ra was a robust measure that declined only about 20% late in life compared to peak values. The lifetime average dose rate varied from 0.08 to 133 mGy day-1 for the 90Sr studies and from 0.21 to 162 mGy day-1 for the 226Ra studies. Lifetime doses to mandible and cervical vertebrae for the intermediate dose levels of fed 90Sr were calculated to be about 40% higher than the skeletal average.

Experimental validation of radiopharmaceutical absorbed dose to mineralized bone tissue.

Therapeutic and palliative uses of bone-seeking radiopharmaceuticals are undergoing clinical trials for human subjects. Radiation dosimetry for these applications is based on the Medical Internal Radiation Dosimetry (MIRD) schema. An experimental method for dosimetry of bone tissue based on electron paramagnetic resonance (EPR) spectrometry is described. Preliminary results for beagle bone exposed to radiopharmaceuticals under clinical conditions have indicated that the EPR dose measurements give approximately the calculated dose, but suggest that the dose distribution may be non-uniform.

Radionuclide distribution dynamics in skeletons of beagles fed 90Sr: correlation with injected 226Ra and 239Pu.

Data for the bone-by-bone redistribution of 90Sr in the beagle skeleton are reported for a period of 4000 d following a midgestation-to-540-d-exposure by ingestion. The partitioned clearance model (PCM) that was originally developed to describe bone-by-bone radionuclide redistribution of 226Ra after eight semimonthly injections at ages 435-535 d has been fitted to the 90Sr data. The parameter estimates for the PCM that describe the distribution and clearance of 226Ra after deposition on surfaces following injection and analogous parameter estimates for 90Sr after uniform deposition in the skeleton as a function of Ca mass are given. Fractional compact bone masses per bone group (mi,COM) are also predicted by the model and compared to measured values; a high degree of correlation (r = 0.84) is found. Bone groups for which the agreement between the model and experimental values of mi,COM was poor had tissue-to-calcium weight ratios about 1.5 times those for bones that agreed well. Metabolically defined "surface" in PCM is initial activity fraction per Ca fraction in a given skeletal component for intravenously injected alkaline earth (Sae) radionuclides; comparisons are made to similarly defined "surface" (Sact) values from 239Pu injection studies. The patterns of Sae and Sact distribution throughout the skeleton are similar.

Localization of bismuth radiotracer in rat kidney following exposure to bismuth.

It has been proposed that alpha emitting 212Bi (t1/2 = 60 min) coupled to tumor-specific antibodies may be a useful radiotherapeutic agent. However, since Bi can accumulate in the kidney, it is necessary to characterize the factors influencing localization of Bi within this tissue in order to evaluate the potential for radiation damage to the renal system. In this study, the localization of Bi radiotracers was determined in kidneys of rats previously exposed and not exposed to mumole quantities of Bi. Following repeated injection of Bi (4 x 14 mumols (3 mg Bi)/kg bw) the element accumulated mainly in the kidney followed by liver, spleen, pancreas, bone, and brain. Kidney copper and liver zinc concentrations were higher in Bi-exposed rats than in non-exposed rats. Within the cytosol, in Bi-exposed rats, Bi radiotracer in the kidney was associated with a metallothionein-like protein (Mt). In contrast, non-exposed rats contained no detectable metallothionein-like proteins in the kidney and the Bi tracer was associated with the hemoglobin fraction of the cell. Thus, when Bi is administered in tracer quantities such as that incorporated for use as a radiopharmaceutical, no induction of, and association with, metallothionein-like proteins should occur. These results suggest that the potential nephrotic effects of 212Bi will be influenced by the individual's previous exposure to Bi-containing drugs, or other metallothionein-inducing insults.

In vitro killing of melanoma by liposome-delivered intracellular irradiation.

To better understand and optimize the mechanism of alpha particle killing of tumors, an in vitro model utilizing liposomes as carrier vehicles was developed to study the killing of melanoma via intracellular alpha-irradiation. The radionuclide 212Pb (lead), with its 10.6-hour half-life and alpha-emitting daughter 212Bi (bismuth), was encapsulated in liposomes to achieve the intracellular irradiation of melanoma cells in culture. In dose-response experiments, B16F10 mouse melanoma cells were incubated with liposomes 212Pb/212Bi bound to dextran 70. Plating efficiency and growth of the melanoma cells cultured on gridded petri dishes after incubation were compared with controls at 24 and 48 hours. Greater than 85% cell killing occurred by 48 hours, with administered radioactivity levels of 1.6 dpm/mumol of lipid/cell, which corresponds to intracellular delivery of five to seven alpha particles per cell. These alpha doses can be exceeded in vivo with recirculation or in a perfusion circuit, and more efficient cytotoxic action may be possible.

Tissue and subcellular distribution of bismuth radiotracer in the rat: considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals.

The whole-body clearance, organ distribution, and subcellular distribution of no-carrier-added and carried-added intraperitoneally administered bismuth radiotracers (205Bi-206Bi) has been determined in Sprague-Dawley rats. Differences in clearance rate kinetics were observed for this study with the administration of neutral solutions of tracers in a carbonate buffer compared to other studies with other chemical forms. The final organ distribution was not strongly dependent on administered chemical form. We provide definitive evidence that bismuth does indeed enter subcellular organelles such as the nucleus and the mitochondria, which had 30-50% and 10-25%, respectively, of activity in kidney tissue. The kidneys were the main sink for radiotracer with uptake ranging from 20 to 50% of total body activity. The calculated energy deposition by recoil nuclei after alpha emission of potentially therapeutically useful 212Bi was found to equal or exceed the alpha energy deposition per organelle if the source is inside the cell nucleus or mitochondria.

Beta spectroscopy with liquid scintillation systems: applications in dosimetry of 90Sr and 90Y.

We have demonstrated that commercially available liquid scintillation counters are adequate for obtaining useful information about the variation of beta spectral shapes as a function of attenuation. A gel scintillation system that permitted the approximation of point source geometry worked well. The spectral shapes predicted by the Fermi equations were reasonably matched with experimental spectra of sources with geometry close to a point source. For energies in the range of 50-2300 keV, we found sufficient linearity of the energy scale and uniformity of detection limits for the direct output of the instrument to be experimentally useful. The gel scintillation system has been used to directly measure the energy distribution of the beta flux coming out of bone samples and incident on the soft tissue of dogs fed 90Sr-90Y from in utero to 540 days of age.

Cyclotron production of no-carrier-added 206Bi (6.24 d) and 205Bi (15.31 d) as tracers for biological studies and for the development of alpha-emitting radiotherapeutic agents.

The production and radiochemical purification of no-carrier-added (NCA) bismuth isotopes (i.e. 6.24 d 206Bi and 15.31 d 205Bi) was studied. The Bi isotopes are intended for use as tracers in biodistribution studies and in the design and testing of alpha-emitting radiotherapeutic agents. The total cross sections and yields for the production of 206Bi and 205Bi from the proton bombardment of natural Pb targets were measured using the stacked-foils technique. A radiochemical method for the separation and purification of NCA Bi radioactivities from a multi-gram Pb target was also tested, modified, and improved to provide aqueous solutions of chemically and biologically useful amounts of NCA 206,205Bi for measuring tissue and subcellular-distributions, and for studies covering several chemical aspects of the development of Pb/Bi radiotherapeutic agents.

Assessment of cortical and trabecular bone distribution in the beagle skeleton by neutron activation analysis.

The distribution of bone calcium between morphologically identifiable cortical and trabecular bone obtained by dissection and quantitated by neutron activation analysis (NAA) is described. The skeleton of a female beagle dog was dissected into approximately 400 pieces and assayed for 49Ca produced in the University of California, Irvine TRIGA reactor. For each of the skeletal sections, we give the initial weight of the alcohol-fixed tissue, which includes cortical bone, trabecular bone, marrow, and cartilage, and a final tissue weight after the marrow and trabecular bone have been dissected away; total section and cortical section calcium weights are reported. The level of detail is represented, for example, by the vertebrae, which were divided into three parts (body, spine, and transverse processes) and by the long bones, which were divided into 10-12 parts such that characterization of the epiphysis, metaphysis, and diaphysis was accomplished. The median percentage cortical calcium values for cervical, thoracic, and lumbar vertebrae were 82%, 56%, and 66%, respectively; however, variation within these groups and among individual vertebral sections was about a factor of 2. For long bones, the median percentage cortical calcium varied from 90-100% in the midshaft to below 50% in the proximal and distal sections. The final calculated cortical tissue-to-calcium mass ratio (TCR) varied from about 4.5 for midshafts of the long bones to about 9 for thoracic vertebral bodies and indicated that the mineral fraction of cortical bone is not constant throughout the skeleton. The ratio of cortical to trabecular calcium in the skeleton was 79.6:20.4.

Squamous cell carcinoma in the jaws of beagles exposed to 90Sr throughout life: beta flux measurements at the mandible and tooth surfaces and a hypothesis for tumorigenesis.

We present the first detailed dose-response measurements for 90Sr-induced soft tissue tumors other than hemopoietic dyscrasias in chronically exposed beagles. Twenty-four of 387 dogs exposed to 90Sr beginning in utero and by continuous ingestion to 540 days of age developed squamous cell carcinoma of the jaw during their lifetime. Eleven of the 24 tumors were observed in dogs ingesting 12 microCi/day and receiving cumulative average doses of 6500-12,000 rad. None of these tumors was observed in dogs ingesting less than 1.25 microCi/day and receiving cumulative skeletal average doses of 2100-3900 rad, but four were observed at this level. The teeth of these animals acquired a 90Sr burden that is not removed by skeletal remodeling. Measurements of the radiation dose to soft tissue adjacent to the mandible and teeth of dogs chronically fed 90Sr indicated the first 10 micron of soft tissue adjacent to teeth received a radiation dose initially about the same as the average skeletal doses. By 2000-3000 days, these tissues received about two to three times that calculated for the average skeletal dose, or about four to six times the mean marrow dose. We suggest that these tumors arise from epithelial rests, which are embryonic tissue trapped in the periodontal membrane between teeth and bone.

Consideration of age-dependent radium retention in people on the basis of the beagle model.

This paper examines in humans the proposition emanating from studies in beagles that initial retention of radium varies in proportion to the calcium addition rate at the time of intake. Human calcium addition rates were scaled from those in beagles, the relative calcium accretion rates in the two species at equivalent stages of skeletal growth providing the scaling factor. The variation of radium retention with age was determined by fitting a modified power function to data on the retention of radium from about 30 to 15000 days following a series of therapeutic injections of 226Ra in humans ranging in age from 18 to 63 yr. The fractional retention R at t days following a single injection of 226Ra was described by R = (1 + t/d)-0.44. The age-dependent parameter d in the retention function was found to be proportional to the calcium addition rate at the time of injection in subjects receiving less than 200 micrograms 226Ra.

Comparative pathogenesis of radium-induced intracortical bone lesions in humans and beagles.

Morphologic changes resulting from the effects of chronic radionuclide toxicity (226Ra) in the skeletons of workers in the radioluminescent dial painting industry with preterminal body burdens ranging from about 1.5 to 0.042 muCi were compared with the pathologic alterations in the skeletons of a group of 38 beagle dogs injected with 1.12 muCi/kg. Similarities observed in the skeletal responses of the two species were the presence of (1) dead bone tissue with delayed resolution, (2) a chronic disturbance in the remodeling mechanism of bone tissue, and (3) radiation-induced bone sarcomas. A detailed analysis of sequential changes in radiographic lesions arising in the beagle skeletons, complemented by histopathologic evaluation at the time of limb amputation or at necropsy, has enabled us to examined the disturbance in the bone remodeling process. The perturbation of critical importance in the generation of primary bone tumors appears to lie in the bone tissue formation and deposition phase of the bone remodeling process and gives rise to a spectrum of histologic patterns which we have termed "radiation osteodystrophy." While some of the newly generated patterns demonstrate indolent behavior with fibrous tissue replacement and bone marrow refill, other sites of bone resorption are replaced by a unique fibro-osseous tissue response resembling fibrous dysplasia or osteoblastoma. Some of these proliferative lesions may undergo progressive malignant degeneration. While the more indolent part of the spectrum was also seen in human skeletal tissues, only premalignant and early sarcomatous stages were seen in canine tissues.

Lifetime bone cancer dose-response relationships in beagles and people from skeletal burdens of 226Ra and 90Sr.

The life-time tumor dose-response relationships observed in beagles injected with 226Ra or fed 90Sr at the University of California, Davis, provide a basis for understanding the induction of bone cancer for these bone-seeking radionuclides and for scaling to people. In these studies 385 dogs were exposed to graded dosage levels of 90Sr and 243 dogs were exposed to graded dosage levels of 226Ra with a total of 159 unexposed controls. The results show different dose-response relationships for bone cancer for the two radionuclides based upon the gravimetric average dose rates and cumulative doses to bone. These relationships were found to be well represented by three-dimensional log-normal dose-response surfaces that yield risk as a function of average dose-rate and time after beginning of exposure. All dose-rates suggested a 100% risk at some later time post-exposure but the time required to reach a given level of risk was long for low dose rates so that there exists a practical threshold in that at lower dose rates individuals may die spontaneously from causes associated with natural aging prior to the expected appearance of radiogenic cancer. The risks to people at various 226Ra body burdens (average skeletal dose rates) are estimated based on the model.

Gut reactions of radioactive nitrite after intratracheal administration in mice.

Intratracheal administration to mice of radioactive nitrite labeled with nitrogen-13 (13NO2-) (half-life, 9.96 minutes) in dosages that do not cause pharmacological perturbation reveals that oxidative and reductive reactions occur in different organs. Oxidation of 13NO2- to radioactive nitrate (13NO3-) predominates in the blood and liver. Reduction of 13NO2- occurs in those mice that harbor intestinal microflora; this reduction does not occur in germ-free mice. The intestinal reduction products include ammonium, glutamate, glutamine, and urea. With a detection limit of about 0.01 percent of the instilled nitrogen-13, no labeled nitrosamines were detected within 30 minutes. Reduced nitrogen-13 is transported out of the intensive into the circulatory system and appears in the urine along with 13NO3-. The biological half-period for 13NO2- destruction is about 7 minutes, and both oxidation and reduction products are formed.